TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)-Reference-Cited by-同舟云学术

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

Published:2019-10-22 Issue: Volume:124 Page:5-13
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Hofman Michael S.¹²,Emmett Louise²³,Violet John¹²,Y. Zhang Alison²⁴,Lawrence Nicola J.²⁴,Stockler Martin²⁴,Francis Roslyn J.⁵⁶,Iravani Amir¹,Williams Scott¹²,Azad Arun¹²,Martin Andrew²⁴,McJannett Margaret²,Davis Ian D.²⁷⁸,

Affiliation:

1. Peter MacCallum Cancer Centre; and Sir Peter MacCallum Department of Oncology; University of Melbourne; Melbourne VIC Australia

2. Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Sydney NSW Australia

3. St Vincent's Hospital; Sydney NSW Australia

4. NHMRC Clinical Trials Centre; University of Sydney; Sydney NSW Australia

5. Department of Nuclear Medicine; Sir Charles Gairdner Hospital; Perth WA Australia

6. Australasian Radiopharmaceutical Trials Network (ARTnet)

7. Eastern Health Clinical School, Monash University; Melbourne VIC Australia

8. Eastern Health; Melbourne VIC Australia

Funder

Prostate Cancer Foundation of Australia

Movember Foundation

Australian Nuclear Science and Technology Organisation

Endocyte

NHMRC Practitioner Fellowship

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14876/fullpdf

Reference38 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Horwich;Ann Oncol,2010

3. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. A retrospective study of the time to clinical endpoints for advanced prostate cancer;Sharifi;BJU Int,2005

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

2. PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-03

3. Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?;Biomedicines;2024-07-08

4. Targeted Radiopharmaceutical Therapy for Bone Metastases;Seminars in Nuclear Medicine;2024-07

5. Prostate Cancer Theranostics With 177Lu-PSMA;Seminars in Nuclear Medicine;2024-07